61.84
前日終値:
$61.44
開ける:
$60.6
24時間の取引高:
485.97K
Relative Volume:
0.67
時価総額:
$4.42B
収益:
$58.89M
当期純損益:
$-240.88M
株価収益率:
-19.95
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
+5.60%
1か月 パフォーマンス:
+9.26%
6か月 パフォーマンス:
+80.45%
1年 パフォーマンス:
+33.94%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc
|
61.84 | 4.39B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-24 | 繰り返されました | B. Riley Securities | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-20 | 再開されました | Stifel | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Pattern recognition hints at Kymera Therapeutics Inc. upsidePortfolio Performance Summary & Stepwise Swing Trade Plans - newser.com
Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $1,829,700.00 in Stock - MarketBeat
Is Kymera Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Pullbacks & Verified Chart Pattern Signals - newser.com
Is Kymera Therapeutics Inc. stock attractive for ETFsTrade Exit Summary & Community Consensus Trade Signals - newser.com
How hedge fund analytics apply to Kymera Therapeutics Inc. stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com
Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing - MarketScreener
KYMR insider trade: CEO option exercise and matching share sales - Stock Titan
What valuation multiples suggest for Kymera Therapeutics Inc. stockJuly 2025 Analyst Calls & Technical Entry and Exit Alerts - newser.com
How to read the order book for Kymera Therapeutics Inc.July 2025 Patterns & Safe Entry Momentum Tips - newser.com
Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance
How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance
Is Kymera Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Earnings & Low Volatility Stock Recommendations - Fundação Cultural do Pará
How analysts rate Kymera Therapeutics Inc. stock todayJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times
Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewswire Inc.
What technical charts say about Kymera Therapeutics Inc. stockJuly 2025 Summary & Community Verified Trade Signals - Fundação Cultural do Pará
Earnings Recap: Why Kymera Therapeutics Inc. stock could outperform in 2025Trend Reversal & Free Expert Approved Momentum Trade Ideas - Fundação Cultural do Pará
Why Kymera Therapeutics Inc. stock could outperform in 2025July 2025 Big Picture & Real-Time Stock Entry Alerts - Fundação Cultural do Pará
Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis - TipRanks
Kymera’s IRF5 degrader shows promise in preclinical lupus, RA studies - Investing.com
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting - Investing News Network
Kymera (NASDAQ: KYMR) shows KT-579 IRF5 degrader activity in lupus, RA at ACR - Stock Titan
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN
Kymera Therapeutics (KYMR) Awaits Key Phase 1b Data Release - GuruFocus
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout (KYMR:NASDAQ) - Seeking Alpha
B. Riley Boosts Price Target on Kymera Therapeutics to $80 From $60, Keeps Buy Rating - MarketScreener
B. Riley Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Kymera Therapeutics (KYMR) Gains Attention with Upcoming Data Re - GuruFocus
Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - sharewise.com
What drives Kymera Therapeutics Inc stock priceTrade Execution Strategies & Exceptional Capital Trading - earlytimes.in
Kymera Therapeutics (NASDAQ:KYMR) Upgraded by Mizuho to "Strong-Buy" Rating - MarketBeat
Kymera Therapeutics, Inc.Common Stock (NQ: KYMR - FinancialContent
BTIG Maintains 'Buy' Rating on KYMR, Raises Price Target to $75 - GuruFocus
BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq
Is Kymera Therapeutics Inc a good long term investmentHigh Dividend Yield Stocks & Free Expert Stock Watchlists - earlytimes.in
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):